We aim for sustainable performance over time to benefit patients, employees, shareholders and society. Solid financial results and maintaining the trust of society underpin our ability to create value.
J.P. Morgan Healthcare Conference
Investors Event Calendar
Third quarter & Nine months 2022 results
Environmental, Social and Governance (ESG)
ESG Updates: Oct 31, 2022 (PDF 0.5 MB) | July 20, 2022 (PDF 0.4 MB) | Apr 27, 2022 (PDF 0.7 MB) | Feb 03, 2022 (PDF 1.7 MB)
Latest updates: Novartis Enterprise Risk Management (PDF 0.2 MB) | Materiality Assessment
We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.
Stocks
Novartis Annual Reporting Suite
Read and download our integrated report, annual regulatory filings, and other disclosures.
Media Releases
Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio
Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5
Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH
Pulse Updates
January 09, 2023
Novartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023
December 16, 2021
Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease
September 28, 2021
FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
September 03, 2021
Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
Investor Relations Contacts
For questions about investor relations or the share registry, please contact our team.
Stay Up-to-Date
Stay connected to the latest news and information from Novartis.
Novartis AG
Lichtstrasse 35
CH-4056 Basel, Switzerland